Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 231

1.

Partial trisomy 21 contributes to T-cell malignancies induced by JAK3-activating mutations in murine models.

Rivera-Munoz P, Laurent AP, Siret A, Lopez CK, Ignacimouttou C, Cornejo MG, Bawa O, Rameau P, Bernard OA, Dessen P, Gilliland GD, Mercher T, Malinge S.

Blood Adv. 2018 Jul 10;2(13):1616-1627. doi: 10.1182/bloodadvances.2018016089.

2.

Crystal structure of B-cell co-receptor CD19 in complex with antibody B43 reveals an unexpected fold.

Teplyakov A, Obmolova G, Luo J, Gilliland GL.

Proteins. 2018 May;86(5):495-500. doi: 10.1002/prot.25485. Epub 2018 Mar 10.

PMID:
29490423
3.

Human IgG subclass cross-species reactivity to mouse and cynomolgus monkey Fcγ receptors.

Derebe MG, Nanjunda RK, Gilliland GL, Lacy ER, Chiu ML.

Immunol Lett. 2018 May;197:1-8. doi: 10.1016/j.imlet.2018.02.006. Epub 2018 Feb 21.

PMID:
29476755
4.

Structural insights into humanization of anti-tissue factor antibody 10H10.

Teplyakov A, Obmolova G, Malia TJ, Raghunathan G, Martinez C, Fransson J, Edwards W, Connor J, Husovsky M, Beck H, Chi E, Fenton S, Zhou H, Almagro JC, Gilliland GL.

MAbs. 2018 Feb/Mar;10(2):269-277. doi: 10.1080/19420862.2017.1412026. Epub 2018 Jan 2.

5.

Structural insights into chemokine CCL17 recognition by antibody M116.

Teplyakov A, Obmolova G, Gilliland GL.

Biochem Biophys Rep. 2017 Dec 9;13:27-31. doi: 10.1016/j.bbrep.2017.11.005. eCollection 2018 Mar.

6.

A new data effort to inform career choices in biomedicine.

Blank R, Daniels RJ, Gilliland G, Gutmann A, Hawgood S, Hrabowski FA, Pollack ME, Price V, Reif LR, Schlissel MS.

Science. 2017 Dec 15;358(6369):1388-1389. doi: 10.1126/science.aar4638. No abstract available.

PMID:
29242335
7.

Homology-based hydrogen bond information improves crystallographic structures in the PDB.

van Beusekom B, Touw WG, Tatineni M, Somani S, Rajagopal G, Luo J, Gilliland GL, Perrakis A, Joosten RP.

Protein Sci. 2018 Mar;27(3):798-808. doi: 10.1002/pro.3353. Epub 2017 Dec 8.

8.

Superior Ophthalmic Vein Access for Embolization of an Indirect Carotid Cavernous Fistula.

Haider AS, Garg P, Leonard D, Osumah T, Khan U, Vayalumkal S, Lee LK, Nguyen P, Gilliland G, Layton KF.

Cureus. 2017 Sep 1;9(9):e1639. doi: 10.7759/cureus.1639.

9.

Modulation of protein A binding allows single-step purification of mouse bispecific antibodies that retain FcRn binding.

Zwolak A, Armstrong AA, Tam SH, Pardinas JR, Goulet DR, Zheng S, Brosnan K, Emmell E, Luo J, Gilliland GL, Chiu ML.

MAbs. 2017 Nov/Dec;9(8):1306-1316. doi: 10.1080/19420862.2017.1375639. Epub 2017 Sep 12.

10.

A coiled conformation of amyloid-β recognized by antibody C706.

Teplyakov A, Obmolova G, Gilliland GL.

Alzheimers Res Ther. 2017 Aug 22;9(1):66. doi: 10.1186/s13195-017-0296-0.

11.

Functional optimization of agonistic antibodies to OX40 receptor with novel Fc mutations to promote antibody multimerization.

Zhang D, Armstrong AA, Tam SH, McCarthy SG, Luo J, Gilliland GL, Chiu ML.

MAbs. 2017 Oct;9(7):1129-1142. doi: 10.1080/19420862.2017.1358838. Epub 2017 Jul 31.

12.

Crystal structure of tissue factor in complex with antibody 10H10 reveals the signaling epitope.

Teplyakov A, Obmolova G, Malia TJ, Wu B, Zhao Y, Taudte S, Anderson GM, Gilliland GL.

Cell Signal. 2017 Aug;36:139-144. doi: 10.1016/j.cellsig.2017.05.004. Epub 2017 May 5.

13.

Crystal structure of CD27 in complex with a neutralizing noncompeting antibody.

Teplyakov A, Obmolova G, Malia TJ, Gilliland GL.

Acta Crystallogr F Struct Biol Commun. 2017 May 1;73(Pt 5):294-299. doi: 10.1107/S2053230X17005957. Epub 2017 Apr 26.

14.

Epitope-dependent mechanisms of CD27 neutralization revealed by X-ray crystallography.

Obmolova G, Teplyakov A, Malia TJ, Wunderler N, Kwok D, Barone L, Sweet R, Ort T, Scully M, Gilliland GL.

Mol Immunol. 2017 Mar;83:92-99. doi: 10.1016/j.molimm.2017.01.005. Epub 2017 Jan 21.

PMID:
28119207
15.

Conformational flexibility of an anti-IL-13 DARPin†.

Teplyakov A, Malia TJ, Obmolova G, Jacobs SA, O'Neil KT, Gilliland GL.

Protein Eng Des Sel. 2017 Jan;30(1):31-37. Epub 2016 Nov 23.

PMID:
27881684
16.

Engineering a targeted delivery platform using Centyrins.

Goldberg SD, Cardoso RM, Lin T, Spinka-Doms T, Klein D, Jacobs SA, Dudkin V, Gilliland G, O'Neil KT.

Protein Eng Des Sel. 2016 Dec;29(12):563-572. Epub 2016 Oct 13.

PMID:
27737926
17.

Engineering antibody therapeutics.

Chiu ML, Gilliland GL.

Curr Opin Struct Biol. 2016 Jun;38:163-73. doi: 10.1016/j.sbi.2016.07.012. Epub 2016 Aug 12. Review.

18.

Structural diversity in a human antibody germline library.

Teplyakov A, Obmolova G, Malia TJ, Luo J, Muzammil S, Sweet R, Almagro JC, Gilliland GL.

MAbs. 2016 Aug-Sep;8(6):1045-63. doi: 10.1080/19420862.2016.1190060. Epub 2016 May 21.

19.

Effect of optic nerve sheath fenestration for idiopathic intracranial hypertension on retinal nerve fiber layer thickness.

Starks V, Gilliland G, Vrcek I, Gilliland C.

Orbit. 2016;35(2):87-90. doi: 10.3109/01676830.2016.1139592. Epub 2016 Feb 29.

PMID:
26928128
20.

Epitope mapping and structural basis for the recognition of phosphorylated tau by the anti-tau antibody AT8.

Malia TJ, Teplyakov A, Ernst R, Wu SJ, Lacy ER, Liu X, Vandermeeren M, Mercken M, Luo J, Sweet RW, Gilliland GL.

Proteins. 2016 Apr;84(4):427-34. doi: 10.1002/prot.24988. Epub 2016 Feb 5.

21.

Induced conformational change in human IL-4 upon binding of a signal-neutralizing DARPin.

Obmolova G, Teplyakov A, Malia TJ, Keough E, Luo J, Sweet R, Jacobs SA, Yi F, Hippensteel R, O'Neil KT, Gilliland GL.

Proteins. 2015 Jun;83(6):1191-7. doi: 10.1002/prot.24815. Epub 2015 May 8.

22.

Effect of resection of an orbital arteriovenous malformation on central venous pressure.

Starks VS, Gilliland G, Hise J, Thacker I, Layton KF.

Proc (Bayl Univ Med Cent). 2015 Apr;28(2):185-7.

23.

Periorbital cellulitis due to cutaneous anthrax.

Gilliland G, Starks V, Vrcek I, Gilliland C.

Int Ophthalmol. 2015 Dec;35(6):843-5. doi: 10.1007/s10792-015-0057-7. Epub 2015 Mar 13. Review.

PMID:
25763844
24.

Use of an ultrasonic bone curette (Sonopet) in orbital and oculoplastic surgery.

Vrcek I, Starks V, Mancini R, Gilliland G.

Proc (Bayl Univ Med Cent). 2015 Jan;28(1):91-3.

25.

Orbital liposarcoma masquerading as a hemangioma.

Vrcek I, Hogan RN, Gilliland G.

Proc (Bayl Univ Med Cent). 2014 Oct;27(4):359-60.

26.

MCL1 and BCL-xL levels in solid tumors are predictive of dinaciclib-induced apoptosis.

Booher RN, Hatch H, Dolinski BM, Nguyen T, Harmonay L, Al-Assaad AS, Ayers M, Nebozhyn M, Loboda A, Hirsch HA, Zhang T, Shi B, Merkel CE, Angagaw MH, Wang Y, Long BJ, Lennon XQ, Miselis N, Pucci V, Monahan JW, Lee J, Kondic AG, Im EK, Mauro D, Blanchard R, Gilliland G, Fawell SE, Zawel L, Schuller AG, Strack P.

PLoS One. 2014 Oct 7;9(10):e108371. doi: 10.1371/journal.pone.0108371. eCollection 2014.

27.

Discovery of biomarkers predictive of GSI response in triple-negative breast cancer and adenoid cystic carcinoma.

Stoeck A, Lejnine S, Truong A, Pan L, Wang H, Zang C, Yuan J, Ware C, MacLean J, Garrett-Engele PW, Kluk M, Laskey J, Haines BB, Moskaluk C, Zawel L, Fawell S, Gilliland G, Zhang T, Kremer BE, Knoechel B, Bernstein BE, Pear WS, Liu XS, Aster JC, Sathyanarayanan S.

Cancer Discov. 2014 Oct;4(10):1154-67. doi: 10.1158/2159-8290.CD-13-0830. Epub 2014 Aug 7.

28.

Protein crystallization with microseed matrix screening: application to human germline antibody Fabs.

Obmolova G, Malia TJ, Teplyakov A, Sweet RW, Gilliland GL.

Acta Crystallogr F Struct Biol Commun. 2014 Aug;70(Pt 8):1107-15. doi: 10.1107/S2053230X14012552. Epub 2014 Jul 23.

29.

Second antibody modeling assessment (AMA-II).

Almagro JC, Teplyakov A, Luo J, Sweet RW, Kodangattil S, Hernandez-Guzman F, Gilliland GL.

Proteins. 2014 Aug;82(8):1553-62. doi: 10.1002/prot.24567. Epub 2014 Apr 26.

PMID:
24668560
30.

Structure and specificity of an antibody targeting a proteolytically cleaved IgG hinge.

Malia TJ, Teplyakov A, Brezski RJ, Luo J, Kinder M, Sweet RW, Almagro JC, Jordan RE, Gilliland GL.

Proteins. 2014 Aug;82(8):1656-67. doi: 10.1002/prot.24545. Epub 2014 Apr 16.

PMID:
24638881
31.

Antibody modeling assessment II. Structures and models.

Teplyakov A, Luo J, Obmolova G, Malia TJ, Sweet R, Stanfield RL, Kodangattil S, Almagro JC, Gilliland GL.

Proteins. 2014 Aug;82(8):1563-82. doi: 10.1002/prot.24554. Epub 2014 Mar 31.

PMID:
24633955
32.

Canonical structures of short CDR-L3 in antibodies.

Teplyakov A, Gilliland GL.

Proteins. 2014 Aug;82(8):1668-73. doi: 10.1002/prot.24559. Epub 2014 Apr 16.

33.

Antibody engineering and therapeutics, The Annual Meeting of the Antibody Society: December 8-12, 2013, Huntington Beach, CA.

Almagro JC, Gilliland GL, Breden F, Scott JK, Sok D, Pauthner M, Reichert JM, Helguera G, Andrabi R, Mabry R, Bléry M, Voss JE, Laurén J, Abuqayyas L, Barghorn S, Ben-Jacob E, Crowe JE Jr, Huston JS, Johnston SA, Krauland E, Lund-Johansen F, Marasco WA, Parren PW, Xu KY.

MAbs. 2014 May-Jun;6(3):577-618. doi: 10.4161/mabs.28421. Epub 2014 Mar 3.

34.

Structural evidence for a constrained conformation of short CDR-L3 in antibodies.

Teplyakov A, Obmolova G, Malia TJ, Luo J, Gilliland GL.

Proteins. 2014 Aug;82(8):1679-83. doi: 10.1002/prot.24522. Epub 2014 Feb 18.

PMID:
24470236
35.

N-terminal β-strand swapping in a consensus-derived alternative scaffold driven by stabilizing hydrophobic interactions.

Luo J, Teplyakov A, Obmolova G, Malia TJ, Chan W, Jacobs SA, O'Neil KT, Gilliland GL.

Proteins. 2014 Jul;82(7):1527-33. doi: 10.1002/prot.24517. Epub 2014 Feb 18.

PMID:
24464739
36.

C-terminal β-strand swapping in a consensus-derived fibronectin Type III scaffold.

Teplyakov A, Obmolova G, Malia TJ, Luo J, Jacobs SA, Chan W, Domingo D, Baker A, O'Neil KT, Gilliland GL.

Proteins. 2014 Jul;82(7):1359-69. doi: 10.1002/prot.24502. Epub 2014 Feb 12.

PMID:
24375666
37.

An engineered Fc variant of an IgG eliminates all immune effector functions via structural perturbations.

Vafa O, Gilliland GL, Brezski RJ, Strake B, Wilkinson T, Lacy ER, Scallon B, Teplyakov A, Malia TJ, Strohl WR.

Methods. 2014 Jan 1;65(1):114-26. doi: 10.1016/j.ymeth.2013.06.035. Epub 2013 Jul 17.

PMID:
23872058
38.

IgG2 Fc structure and the dynamic features of the IgG CH2-CH3 interface.

Teplyakov A, Zhao Y, Malia TJ, Obmolova G, Gilliland GL.

Mol Immunol. 2013 Nov;56(1-2):131-9. doi: 10.1016/j.molimm.2013.03.018. Epub 2013 Apr 28.

PMID:
23628091
39.

Evidence of mTOR Activation by an AKT-Independent Mechanism Provides Support for the Combined Treatment of PTEN-Deficient Prostate Tumors with mTOR and AKT Inhibitors.

Zhang W, Haines BB, Efferson C, Zhu J, Ware C, Kunii K, Tammam J, Angagaw M, Hinton MC, Keilhack H, Paweletz CP, Zhang T, Winter C, Sathyanarayanan S, Cheng J, Zawel L, Fawell S, Gilliland G, Majumder PK.

Transl Oncol. 2012 Dec;5(6):422-9. Epub 2012 Dec 1.

40.

Mechanisms of self-association of a human monoclonal antibody CNTO607.

Bethea D, Wu SJ, Luo J, Hyun L, Lacy ER, Teplyakov A, Jacobs SA, O'Neil KT, Gilliland GL, Feng Y.

Protein Eng Des Sel. 2012 Oct;25(10):531-7. Epub 2012 Aug 22.

PMID:
22915597
41.

A novel solution for superficially placed calcium hydroxylapatite (Radiesse) in the inferior eyelid.

Vrcek IM, Malouf P, Gilliland GD.

Orbit. 2012 Dec;31(6):431-2. doi: 10.3109/01676830.2012.694557. Epub 2012 Jun 25.

PMID:
22731869
42.

Lateral clustering of TLR3:dsRNA signaling units revealed by TLR3ecd:3Fabs quaternary structure.

Luo J, Obmolova G, Malia TJ, Wu SJ, Duffy KE, Marion JD, Bell JK, Ge P, Zhou ZH, Teplyakov A, Zhao Y, Lamb RJ, Jordan JL, San Mateo LR, Sweet RW, Gilliland GL.

J Mol Biol. 2012 Aug 3;421(1):112-24. doi: 10.1016/j.jmb.2012.05.006. Epub 2012 May 9.

43.

Structural basis for high selectivity of anti-CCL2 neutralizing antibody CNTO 888.

Obmolova G, Teplyakov A, Malia TJ, Grygiel TL, Sweet R, Snyder LA, Gilliland GL.

Mol Immunol. 2012 Jun;51(2):227-33. doi: 10.1016/j.molimm.2012.03.022. Epub 2012 Apr 7.

PMID:
22487721
44.

Biologics and molecular recognition: Mike Brigham-Burke memorial issue.

Canziani G, Nemeth JF, Sweet R, Scallon B, Gilliland GL, Almagro JC, Knight D.

J Mol Recognit. 2012 Mar;25(3):99-102. doi: 10.1002/jmr.2157. No abstract available.

PMID:
22407973
45.

Design of novel FN3 domains with high stability by a consensus sequence approach.

Jacobs SA, Diem MD, Luo J, Teplyakov A, Obmolova G, Malia T, Gilliland GL, O'Neil KT.

Protein Eng Des Sel. 2012 Mar;25(3):107-17. doi: 10.1093/protein/gzr064. Epub 2012 Jan 12.

PMID:
22240293
46.

Leveraging SBDD in protein therapeutic development: antibody engineering.

Gilliland GL, Luo J, Vafa O, Almagro JC.

Methods Mol Biol. 2012;841:321-49. doi: 10.1007/978-1-61779-520-6_14. Review.

PMID:
22222459
47.

Crystallization of a challenging antigen-antibody complex: TLR3 ECD with three noncompeting Fabs.

Malia TJ, Obmolova G, Luo J, Teplyakov A, Sweet R, Gilliland GL.

Acta Crystallogr Sect F Struct Biol Cryst Commun. 2011 Oct 1;67(Pt 10):1290-5. doi: 10.1107/S1744309111030983. Epub 2011 Sep 30.

48.

Antigen recognition by antibody C836 through adjustment of V(L)/V(H) packing.

Teplyakov A, Obmolova G, Malia T, Gilliland G.

Acta Crystallogr Sect F Struct Biol Cryst Commun. 2011 Oct 1;67(Pt 10):1165-7. doi: 10.1107/S1744309111027746. Epub 2011 Sep 24.

49.

Antibody modeling assessment.

Almagro JC, Beavers MP, Hernandez-Guzman F, Maier J, Shaulsky J, Butenhof K, Labute P, Thorsteinson N, Kelly K, Teplyakov A, Luo J, Sweet R, Gilliland GL.

Proteins. 2011 Nov;79(11):3050-66. doi: 10.1002/prot.23130. Epub 2011 Sep 21.

PMID:
21935986
50.

Crystal structure of human germline antibody 3-23/B3.

Malia TJ, Obmolova G, Almagro JC, Gilliland GL, Teplyakov A.

Mol Immunol. 2011 Jul;48(12-13):1586-8. doi: 10.1016/j.molimm.2011.04.020. Epub 2011 May 24.

PMID:
21605907

Supplemental Content

Loading ...
Support Center